Hanmi Pharmaceutical’s EPPE Obesity Treatment Begins Prescriptions in South Korea
EPPE Launch and Reported Price
Hanmi Pharmaceutical’s EPPE began being prescribed in South Korea on the 29th of the previous month, according to the supplied report; the month and year were not specified. The report identifies the treatment as efpeglenatide and gives an approximate price of $130 for the first four weeks.
That figure is reported as about 40% lower than the price of Mounjaro. The supplied information does not specify the pricing basis, the products or doses used for comparison, or whether the amount includes all treatment-related costs. It also provides no clinical results or insurance coverage details.
What the Announcement Says
- EPPE is described as South Korea’s first domestically developed obesity treatment.
- Prescriptions reportedly began on the 29th of the previous month.
- The reported introductory four-week price is approximately $130.
Information Still Needed
The short announcement does not include efficacy or safety data, prescribing criteria, or details about regulatory review and reimbursement. Readers should consult the original source and official product information for further details.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.